🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

35 results for “trastuzumab” Clear

  1. Trastuzumab

    United Therapeutics Europe Ltd

    Metastatic Colon Adenocarcinoma

    phase 2 mab terminated

    1 trial

  2. Trastuzumab

    United Therapeutics Europe Ltd

    Metastatic Colorectal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  3. Trastuzumab

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

    First Tracks Biotherapeutics

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  5. A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Refractory metastatic Her2 positive breast cancer

    phase 1 other active

    1 trial

  6. A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

  7. Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

    Daiichi Sankyo Europe GmbH

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  8. Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Daiichi Sankyo Europe GmbH

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

  9. Trastuzumab Rezetecan

    First Tracks Biotherapeutics

    Breast Cancer

    approved small molecule active

    1 trial

  10. 89Zr-trastuzumab

    United Therapeutics Europe Ltd

    Breast Cancer Metastases

    other completed

    1 trial

  11. Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab

    First Tracks Biotherapeutics

    Breast Cancers

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources